GPR162 and Alzheimer disease: First, the study showed that the proportion of GABRD+/GPR162+ EVs carrying pTau217 accurately distinguished AD patients from HC (AUC = 0.9166, GABRD+-carrying pTau217 EVs; 0.8183, GPR162+-carrying pTau217 EVs) (Additional file 2: Table S4).